News

Basel, Switzerland. October 22, 2024, 7am CEST BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria, announced today that it has joined the EU-funded RespiriNTM programme, an 8-year journey exploring multiple approaches to determine new targets for […]

Basel, Switzerland. October 16, 2024, 7am CEST BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria, announced today the completion of the last patient’s last visit in the Phase 2 clinical trial with its lead asset BV100,

Basel, Switzerland. September 24, 2024, 7am CEST BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria, in collaboration with its partners in the AMR Accelerator programme, call for sustainable investment in antimicrobial research and development. Antibiotic resistance

Basel, Switzerland. September 11, 2024, 7am CEST BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria, announced today the strategic investment by investment firm Guangzhou Sino-Israel Bio-Industry Investment Fund 2 LLP (GIBF) of US$ 6m (approximately CHF

Basel, Switzerland. June 4, 2024, 7am CEST     BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria, announced today that it has received a non-dilutive award from the CF AMR Syndicate of up to GBP 500’000,

Basel, Switzerland. May 7, 2024, 7am CEST BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria, announced today the expansion of its strategic collaboration with the global biopharma company GSK plc (LSE/NYSE: GSK) to accelerate the clinical

Basel, Switzerland. March 5, 2024, 9am CET BioVersys and GSK successfully complete IMI2 programme reaching clinical milestone BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria, announced today that in partnership with GSK they have successfully completed

Basel, Switzerland. January 23, 2024, 9am CET BioVersys AG and Helmholtz Centre for Infection Research join forces to accelerate AMR research and development BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria, announced today that it has

Basel, Switzerland. December 12, 2023, 9am CET BioVersys receives U.S. FDA orphan-drug designation for alpibectir and ethionamide fixed-dose combination for treatment of tuberculosis BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria, announced today that the U.S.

Basel, Switzerland. November 01, 2023, 9am CET Hernan Levett joins BioVersys AG as new CFO to support the next stage of corporate development BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria, announced today that Hernan Levett